Ortho Clinical Diagnostics (OCDX) Announces 22M Share Secondary Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Ortho Clinical Diagnostics Announces Secondary Offering of Ordinary Shares
September 7, 2021 4:21 PM EDTRARITAN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the Company), one of the worlds largest pure-play in vitro diagnostics companies, today announced that one of its shareholders (the Selling Shareholder), an affiliate of The Carlyle Group, intends to offer for sale in an underwritten secondary offering 22,000,000 ordinary shares of the Company pursuant to a registration statement filed by the Company with the U.S. Securities and Exchange Commission (the SEC). Additionally, the Selling Shareholder expects to grant the underwriters a 30-day option to purchase up to an additional... More
